The CHRNA2 Gene Epilepsy Nocturnal Frontal Lobe Type 4 Genetic Test is a specialized diagnostic procedure available at DNA Labs UAE. This test is designed to identify mutations in the CHRNA2 gene, which have been linked to epilepsy nocturnal frontal lobe type 4 (ENFL4). ENFL4 is a rare form of epilepsy characterized by nocturnal seizures with frontal lobe origin, affecting individuals during sleep. The CHRNA2 gene plays a crucial role in the proper functioning of neuronal nicotinic acetylcholine receptors, which are essential for normal neurological activity. Mutations in this gene can disrupt normal brain activity, leading to the development of epilepsy.
The test is conducted through a detailed analysis of the patient's DNA, extracted from a blood sample, to detect any genetic anomalies in the CHRNA2 gene. This genetic testing is pivotal for individuals with a family history of ENFL4 or those exhibiting symptoms, as it provides a definitive diagnosis, enabling targeted treatment and management of the condition.
The cost of the CHRNA2 Gene Epilepsy Nocturnal Frontal Lobe Type 4 Genetic Test at DNA Labs UAE is 4400 AED. This price reflects the comprehensive nature of the test, covering the expenses of the genetic analysis, the expertise of the medical professionals involved, and the use of advanced laboratory technology to ensure accurate results. Undergoing this test at DNA Labs UAE offers patients access to state-of-the-art genetic testing services, with reliable results that can significantly impact the management and understanding of epilepsy nocturnal frontal lobe type 4.
The SCARB2 Gene Epilepsy Progressive Myoclonic Type 4 with or without Renal Failure Genetic Test is a specialized diagnostic tool available at DNA Labs UAE, designed to identify mutations in the SCARB2 gene. This gene is crucial for understanding a rare form of epilepsy known as Progressive Myoclonic Epilepsy Type 4 (EPM4), which may also be associated with renal failure in some cases. The condition is characterized by progressive muscle jerks, seizures, and, in some instances, kidney dysfunction. Identifying mutations in the SCARB2 gene can help in confirming the diagnosis, allowing for a better-informed approach to treatment and management of the condition.
The test is priced at 4400 AED and involves analyzing the patient's DNA to detect any genetic abnormalities that could be responsible for the condition. By opting for this test at DNA Labs UAE, patients and healthcare providers can gain crucial insights into the genetic underpinnings of the disease, paving the way for personalized treatment plans and interventions. This genetic test is an essential tool for those suspected of having this form of epilepsy, offering hope for improved quality of life through targeted therapies and management strategies.
The PRICKLE2 Gene Epilepsy Progressive Myoclonic Type 5 Genetic Test is a specialized diagnostic assessment conducted at DNA Labs UAE. This test is designed to identify mutations in the PRICKLE2 gene, which have been associated with Progressive Myoclonic Epilepsy type 5 (EPM5). EPM5 is a rare genetic disorder characterized by myoclonus, seizures, and, in some cases, progressive neurological decline. The identification of mutations in the PRICKLE2 gene through this test is crucial for accurate diagnosis, which can significantly influence management and treatment strategies for affected individuals. The cost of the test is 4400 AED, reflecting the sophisticated technology and expertise required to accurately analyze genetic material for the specific mutations linked to this form of epilepsy. By opting for this test at DNA Labs UAE, patients and healthcare providers can expect reliable and actionable genetic insights that can help in tailoring individualized care plans.
The KCNC1 Gene Epilepsy Progressive Myoclonic Type 7 Genetic Test is a specialized diagnostic examination offered by DNA Labs UAE, designed to identify mutations in the KCNC1 gene that are associated with Progressive Myoclonic Epilepsy Type 7 (EPM7). This condition is a rare neurological disorder characterized by a combination of myoclonus (sudden, involuntary muscle jerks) and seizures, alongside other potential symptoms such as cognitive decline and ataxia. The test plays a crucial role in the accurate diagnosis and management of the disorder, allowing for targeted therapeutic strategies and genetic counseling for affected families.
Conducted at DNA Labs UAE, a leading facility in genetic diagnostics, the test involves collecting a DNA sample, typically through a blood draw or cheek swab, and examining it for specific genetic alterations in the KCNC1 gene. These mutations disrupt the normal function of Kv3.1, a protein essential for the rapid firing of neurons, leading to the symptoms observed in EPM7.
The cost of the KCNC1 Gene Epilepsy Progressive Myoclonic Type 7 Genetic Test is 4400 AED. Given the complexity of genetic testing and the specialized analysis involved, this cost reflects the comprehensive approach taken by DNA Labs UAE to ensure accurate and reliable results. For patients and families facing the challenges of Progressive Myoclonic Epilepsy Type 7, this test offers a valuable resource for diagnosis and future planning.
The SYN1 gene, associated with X-linked epilepsy accompanied by learning disabilities and behavioral disorders, is a critical area of genetic study. This condition manifests through a range of symptoms including seizures, cognitive challenges, and various behavioral issues due to mutations in the SYN1 gene, which plays a significant role in synaptic transmission in the brain. Understanding the genetic basis of these disorders can lead to more targeted and effective treatments.
At DNA Labs UAE, individuals can undergo a genetic test specifically designed to identify mutations in the SYN1 gene. This test is crucial for families seeking answers to unexplained symptoms of epilepsy, learning disabilities, and behavioral disorders that follow an X-linked inheritance pattern. Early diagnosis through genetic testing can significantly impact management strategies, allowing for personalized treatment plans that address both the neurological and behavioral aspects of the condition.
The cost of the SYN1 gene epilepsy genetic test at DNA Labs UAE is set at 4400 AED. This investment includes a comprehensive analysis aimed at detecting mutations within the SYN1 gene that are linked to the disorder. By choosing to undergo this test, individuals gain valuable insights into their genetic makeup, empowering them and their healthcare providers with the information needed to make informed decisions about their health and treatment options.
The CHD2 gene epileptic encephalopathy childhood-onset genetic test is a specialized diagnostic tool designed to identify mutations in the CHD2 gene, which have been associated with the development of early-onset epileptic encephalopathy. This condition is characterized by frequent seizures and significant neurodevelopmental delays occurring in childhood. The CHD2 gene plays a crucial role in brain development and function, and mutations in this gene can lead to various neurological issues, including epilepsy.
Conducted at DNA Labs UAE, this test provides a comprehensive analysis of the CHD2 gene to detect any genetic abnormalities that may contribute to the condition. By identifying specific mutations, the test can offer valuable information for the diagnosis, treatment planning, and management of affected individuals. It involves collecting a DNA sample, typically through a blood draw or cheek swab, which is then analyzed in the laboratory using advanced genetic sequencing techniques.
The cost of the CHD2 gene epileptic encephalopathy childhood-onset genetic test at DNA Labs UAE is 4400 AED. This investment in testing can be crucial for families seeking answers to their child's developmental and epileptic challenges, enabling them to access targeted therapies and interventions that can significantly improve the quality of life for those affected by this condition.
The MAPK10 gene, associated with the Lennox-Gastaut type of epileptic encephalopathy, is a critical focus for genetic testing in the field of neurology. This rare but severe form of epilepsy is characterized by multiple types of seizures, cognitive dysfunction, and a particular EEG pattern. Understanding the genetic underpinnings of this condition can significantly impact treatment plans and patient outcomes.
DNA Labs UAE offers a specialized genetic test targeting the MAPK10 gene to identify mutations that may contribute to Lennox-Gastaut syndrome. This test is a valuable tool for clinicians in diagnosing and managing this complex form of epilepsy, providing insights that can guide personalized treatment strategies.
The cost of the MAPK10 gene epileptic encephalopathy Lennox-Gastaut type genetic test at DNA Labs UAE is 4400 AED. The test is conducted using state-of-the-art genetic sequencing technologies, ensuring high accuracy and reliability. By identifying specific genetic markers, this test can help in confirming the diagnosis, which is crucial for implementing the most effective interventions as early as possible.
For families and individuals facing the challenges of Lennox-Gastaut syndrome, this genetic test represents a step towards a more tailored and informed approach to managing the condition, offering hope for better quality of life and outcomes.
The KCNA1 Gene Episodic Ataxia Type 1 Genetic Test is a specialized diagnostic procedure available at DNA Labs UAE, designed to identify mutations in the KCNA1 gene, which are linked to Episodic Ataxia Type 1 (EA1). EA1 is a rare genetic disorder characterized by brief episodes of ataxia, or lack of muscle coordination, often accompanied by myokymia (involuntary muscle twitching). These episodes can be triggered by stress, sudden movements, or physical exertion.
The test involves collecting a DNA sample, usually through a blood draw or a cheek swab, which is then analyzed in the laboratory for the presence of specific genetic alterations in the KCNA1 gene. Identifying these mutations can confirm a diagnosis of EA1, enabling targeted management and treatment strategies for affected individuals.
The cost of the KCNA1 Gene Episodic Ataxia Type 1 Genetic Test at DNA Labs UAE is 4400 AED. This investment covers the comprehensive analysis required to detect the relevant genetic mutations, offering invaluable insights for patients and their families. By confirming a diagnosis, the test can facilitate informed decisions regarding treatment options, potential lifestyle adjustments, and genetic counseling for family planning.
The CACNA1A gene episodic ataxia type 2 genetic test is a specialized diagnostic tool designed to identify mutations in the CACNA1A gene, which is known to cause episodic ataxia type 2 (EA2). EA2 is a rare, inherited neurological disorder characterized by episodes of ataxia (lack of muscle coordination), vertigo, and, in some cases, migraine. The condition is autosomal dominant, meaning a mutation in just one of the two copies of the gene can lead to the disorder.
The test is conducted at DNA Labs UAE, a leading facility in genetic testing and analysis. It involves collecting a DNA sample, typically through a blood draw or a cheek swab, which is then examined for specific mutations in the CACNA1A gene that are associated with EA2. This genetic testing is crucial for accurate diagnosis, allowing for appropriate management and treatment of the condition.
The cost of the CACNA1A gene episodic ataxia type 2 genetic test at DNA Labs UAE is 4400 AED. While the price may seem significant, the test provides invaluable information for affected individuals and their families, offering insights into the genetic basis of their condition and guiding decisions regarding treatment and genetic counseling.
The CACNB4 Gene Episodic Ataxia Type 5 Genetic Test is a specialized diagnostic procedure available at DNA Labs UAE, aimed at identifying mutations in the CACNB4 gene, which are associated with Episodic Ataxia Type 5 (EA5). EA5 is a rare genetic disorder characterized by intermittent episodes of ataxia, or lack of voluntary coordination of muscle movements, including gait abnormality, as well as other potential symptoms such as vertigo, dysarthria, and nystagmus. The CACNB4 gene encodes a crucial subunit of the voltage-dependent calcium channel, playing a vital role in the proper functioning of neuronal cells. Mutations in this gene can disrupt calcium signaling, leading to the symptoms observed in EA5.
This genetic test is crucial for individuals exhibiting symptoms suggestive of episodic ataxia or for those with a family history of the condition, as it provides a definitive diagnosis by identifying the presence of specific mutations in the CACNB4 gene. Early and accurate diagnosis can aid in the management of symptoms and in making informed decisions regarding treatment and lifestyle adjustments.
The test is conducted at DNA Labs UAE, a facility known for its advanced genetic testing services. The cost of the CACNB4 Gene Episodic Ataxia Type 5 Genetic Test is 4400 AED. The process involves collecting a DNA sample, typically through a blood draw or a cheek swab, which is then analyzed in the laboratory to detect mutations in the CACNB4 gene. Results from this test can provide valuable insights for patients and their families, guiding healthcare decisions and potentially improving quality of life for those affected by EA5.
